Despite a global pandemic and social distancing measures threatening to hamper influenza vaccinations last season, CSL’s Seqirus managed to deliver a record number of flu shots—and it’s preparing to match that this season.
Seqirus, one of the largest flu vaccine makers in the world, shipped roughly 130 million flu vaccine doses globally last year, driving sales for the division up an impressive 30% at constant exchange rates to $1.7 billion, CSL reported in an annual filing on Wednesday.
The results for CSL’s Seqirus last year were “exceptionally strong,” driven primarily by its flu shot products amid the COVID-19 pandemic, CSL chief Paul Perreault said during a call with analysts.
